Prospective evaluation of serum sarcosine and risk of prostate cancer in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
暂无分享,去创建一个
Tamra E. Meyer | R. Hoover | T. Veenstra | Kai Yu | D. Albanes | G. Andriole | S. Berndt | H. Issaq | A. Hsing | L. Chu | Stella Koutros | Wen-Yi Huang | T. Meyer | S. Fox
[1] John T. Wei,et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression , 2009, Nature.
[2] J. Gohagan,et al. Etiologic and early marker studies in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial. , 2000, Controlled clinical trials.
[3] S Kamen,et al. The task force. , 1976, Journal of hospital dental practice.
[4] V. Mootha,et al. Metabolite profiles and the risk of developing diabetes , 2011, Nature Medicine.
[5] G. Wittert,et al. Androgens, diabetes and prostate cancer. , 2012, Endocrine-related cancer.
[6] A. Hewavitharana. Re: Florian Jentzmik, Carsten Stephan, Kurt Miller, et al. Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours. Eur Urol 2010;58:12-8. , 2010, European urology.
[7] N. Rothman,et al. LINE-1 Methylation Levels in Leukocyte DNA and Risk of Renal Cell Cancer , 2011, PloS one.
[8] P. Ditonno,et al. Serum sarcosine increases the accuracy of prostate cancer detection in patients with total serum PSA less than 4.0 ng/ml , 2012, The Prostate.
[9] A. Stenzl,et al. Re: Florian Jentzmik, Carsten Stephan, Kurt Miller, et al. Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours. Eur Urol 2010;58:12-8. , 2010, European urology.
[10] X. Yao,et al. The Prostate 71 : 700 ^ 710 ( 2011 ) AMultiplexModelof CombiningGene-Based , Protein-Based , andMetabolite-BasedWith Positive andNegativeMarkers inUrine for the EarlyDiagnosis of ProstateCancer , 2011 .
[11] Yan Liu,et al. Hormonal profile of diabetic men and the potential link to prostate cancer , 2008, Cancer Causes & Control.
[12] A. Shojaie,et al. Metabolomic Profiling Reveals a Role for Androgen in Activating Amino Acid Metabolism and Methylation in Prostate Cancer Cells , 2011, PloS one.
[13] Tamra E. Meyer,et al. A reproducible and high-throughput HPLC/MS method to separate sarcosine from α- and β-alanine and to quantify sarcosine in human serum and urine. , 2011, Analytical chemistry.
[14] G. Kristiansen,et al. Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours. , 2010, European urology.
[15] R. Hayes,et al. Endogenous sex hormones and the risk of prostate cancer: A prospective study , 2007, International journal of cancer.
[16] P. Clark,et al. Serum Methionine Metabolites Are Risk Factors for Metastatic Prostate Cancer Progression , 2011, PloS one.
[17] P C Prorok,et al. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. , 2000, Controlled clinical trials.
[18] Anssi Auvinen,et al. Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC). , 2012, European urology.
[19] X. Yao,et al. Efforts to resolve the contradictions in early diagnosis of prostate cancer: a comparison of different algorithms of sarcosine in urine , 2011, Prostate Cancer and Prostatic Diseases.
[20] E. Giovannucci,et al. A Meta-analysis of Diabetes Mellitus and the Risk of Prostate Cancer , 2006, Cancer Epidemiology Biomarkers & Prevention.
[21] J. Schalken. Is urinary sarcosine useful to identify patients with significant prostate cancer? The trials and tribulations of biomarker development. , 2010, European urology.
[22] John T. Wei,et al. Re: Florian Jentzmik, Carsten Stephan, Kurt Miller, et al. Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours. Eur Urol 2010;58:12-8. , 2010, European Urology.
[23] Kurt Miller,et al. Sarcosine in prostate cancer tissue is not a differential metabolite for prostate cancer aggressiveness and biochemical progression. , 2011, The Journal of urology.
[24] S. Bonovas,et al. Diabetes mellitus and risk of prostate cancer: a meta-analysis , 2004, Diabetologia.
[25] L. Bohm,et al. Plasma sarcosine does not distinguish early and advanced stages of prostate cancer. , 2012, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.
[26] Stacey A. Kenfield,et al. Smoking and prostate cancer survival and recurrence. , 2011, JAMA.
[27] T. Veenstra,et al. Is sarcosine a biomarker for prostate cancer? , 2011, Journal of separation science.
[28] Tao-Tao Liu,et al. GC/MS-based metabolomic approach to validate the role of urinary sarcosine and target biomarkers for human prostate cancer by microwave-assisted derivatization , 2011, Analytical and bioanalytical chemistry.
[29] H. Baba,et al. LINE-1 Hypomethylation in Noncancerous Esophageal Mucosae is Associated with Smoking History , 2012, Annals of Surgical Oncology.
[30] P. Carroll,et al. Smoking influences aberrant CpG hypermethylation of multiple genes in human prostate carcinoma , 2006, Cancer.
[31] J. Gohagan,et al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. , 2012, Journal of the National Cancer Institute.
[32] D. Albanes,et al. Diabetes mellitus and prostate cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial , 2008, Cancer Causes & Control.
[33] N. Rifai,et al. Association between C-Peptide Concentration and Prostate Cancer Incidence in the CLUE II Cohort Study , 2010, Cancer Prevention Research.
[34] M. Blankenstein,et al. Serum sarcosine is not a marker for prostate cancer , 2010, Annals of clinical biochemistry.
[35] Yikyung Park,et al. Cigarette Smoking and Prostate Cancer in a Prospective US Cohort Study , 2009, Cancer Epidemiology, Biomarkers & Prevention.